Basic Information
OZEMPIC 1MG/DOSE SOLUTION FOR INJECTION IN PRE-FILLED PEN 1.34MG/ML
INJECTION, SOLUTION
Regulatory Information
SIN16164P
April 21, 2021
Prescription Only
Therapeutic
SUBCUTANEOUS
August 10, 2023
May 30, 2025
XA10BJ06
Company Information
NOVO NORDISK PHARMA (SINGAPORE) PTE LTD
NOVO NORDISK PHARMA (SINGAPORE) PTE LTD
Active Ingredients
Strength: 1.34mg/ml
Detailed Information
Contraindications
**Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in _List of excipients_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
Indication Information
**Therapeutic indications** Ozempic® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise - as monotherapy when metformin is considered inappropriate due to intolerance or contraindications - in addition to other medicinal products for the treatment of diabetes. To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease (see Pharmacodynamic Properties – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).